ARTICLE | Clinical News
Vosoritide: Ph III started
December 14, 2016 11:02 PM UTC
BioMarin began a double-blind, placebo-controlled, international Phase III trial to evaluate daily vosoritide for 52 weeks in about 110 patients ages 5-14. Patients who complete the trial may be eligi...
BCIQ Company Profiles
BCIQ Target Profiles